{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.0","upperLimit":"19.0","value":"16.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"Time to platelet engraftment will be analyzed by the Kaplan-Meier method. The time to engraftment of platelets is defined as the time from day 0 to the first of seven consecutive Complete Blood Counts (CBCs) obtained on different days after transplantation during which the platelet count is at least 20 x109/l. The CBCs obtained should be at least seven days after the most recent platelet transfusion. The median and 95% confidence intervals will be provided. Only patients achieving platelet engraftment will be included.","dispersionType":"95% Confidence Interval","groups":[{"description":"Meloxicam and Filgrastim will be administered in fixed doses to each patient enrolled on this study. The treatments will be administered in a staggered dose schedule for a total treatment duration of 7 days prior to apheresis.\n\n15 mg tablets of Meloxicam will be taken orally for 5 consecutive days.\n\n10 µg/kg of Filgrastim will be subcutaneously injected for 5 consecutive days. Filgrastim may be subcutaneously injected for an additional 3 days if patients do not meet the primary endpoint for cell collection.\n\nMeloxicam: 15 mg tablets of Meloxicam will be taken orally in the morning, with or without food.\n\nFilgrastim: Filgrastim will be subcutaneously injected in one or two sites at home.","id":"OG000","title":"Treatment Group"}],"paramType":"MEDIAN","populationDescription":"All patients who received a transplant and engrafted. All patients were analyzed together since the definition for platelet engraftment is the same regardless of disease and only the time until overall platelet engraftment was the outcome of interest.","reportingStatus":"POSTED","timeFrame":"within 100 days of transplant","title":"Time to Platelet Engraftment","type":"SECONDARY","unitOfMeasure":"days"}